Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03231878 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
A Phase 2 study, sponsored by Minoryx Therapeutics, S.L..
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT03231878 is a Phase 2 study that has completed, run by Minoryx Therapeutics, S.L.. The registered enrollment target is 105 participants.
The verdict
NCT03231878, a Phase 2 study, has completed, sponsored by Minoryx Therapeutics, S.L..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter, two parallel-group study in male patients with the AMN phenotype of X-linked adrenoleukodystrophy (X-ALD) to assess the efficacy and safety of MIN-102 treatment. Study sites will consist of specialist referral centers experienced in the management of adrenoleukodystrophy (ALD).
Interventions
- DRUG Placebos
- DRUG MIN-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2025-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03231878
The ClinicalTrials.gov registry entry for NCT03231878 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minoryx Therapeutics, S.L., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03231878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03231878 about?
NCT03231878 is a clinical study titled "A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.". This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter, two parallel-group study in male patients with the AMN phenotype of X-linked adrenoleukodystrophy (X-ALD) to assess the efficacy and safety of MIN-102 treatment. Study sites will consist of specialist referral centers...
What is the current status of trial NCT03231878?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2017-12-08. Estimated completion is 2025-03-06.
What interventions are being tested in trial NCT03231878?
The interventions under investigation include: Placebos (DRUG), MIN-102 (DRUG).
Who is sponsoring clinical trial NCT03231878?
This trial is sponsored by Minoryx Therapeutics, S.L., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.